Company Profile

Top Page > Company Profile > Our Business > Core Technologies

Core Technologies

MBL has had solid antibody development and production technologies as its core competencies since the beginning of the company.
In addition to these technologies, MBL fully utilizes genetic engineering and protein expression/purification technologies in the development of products, such as in vitro diagnostics and research reagents.

Antibody Acquisition Technologies

MBL has introduced and established systems for generating recombinant*1 antibodies by directly extracting antibody genes from one single cell antibody-producing B lymphocyte, as a technological approach to acquire higher-quality antigen-specific antibodies, in addition to conventional antibody production technologies. MBL’s new technology is theoretically capable of yielding target antibody-generating genes with an extremely high probability, and thereby promises to be dozens of times more efficient than conventional methods of producing monoclonal antibodies using hybridoma technologies. Efficient capture of a wide variety of specific antibodies is extremely advantageous in selecting antibodies best suited for various measurement systems.

Antibody Production Technologies

MBL began researching and implementing antibody production, purification, and processing technologies by using polyclonal antibodies derived from animal sera, followed by the era of technologies using mouse monoclonal antibodies. The company’s technology has now shifted to the current new generation of recombinant antibodies. Recombinant antibody technologies are powerfully effective in realizing drastic productivity improvement and cost cutting. The mass production of low-cost, high-quality antibodies will substantially increase the competitiveness of finished products on the market.

Protein Production Technologies

Technologies for recombinant antigen-protein expression and purification are extremely important for growth and innovation in MBL’s core business of autoantibody*2 measurement reagents.
MBL scrutinizes properties of antigen proteins obtained from expression systems such as E. coli, insect cells, and mammalian cells and selects optimal antigen proteins in terms of biological performance, factory productivity, and economic efficiency. Furthermore, to supply high-purity and quality reagents in the market, target antigens are purified by a high grade liquid chromatography or a method of the anity purification with high performance antibodies generated in-house to epitope tags which are genetically conjugated with the target proteins.

Clinical Diagnostics Development

Immunological Assay Kits and Reagents

Utilizing its own antibody and protein engineering technologies, MBL is developing more unique in vitro diagnostics and various measurement systems that will yield novel in vitro diagnostics in the future.
In 2010, MBL added and launched a new business line of chemiluminescent immunoassays (CLEIA) to the company’s conventional business with ELISA method. CLEIA provides you fully automated measurement of autoantibodies and a drastic time reduction in measurement time, and have now become the company’s flagship business.
Further, the company has invested a substantial amount of resources into the development of latex agglutination reagents to offer a more versatile measurement system, and has achieved detection sensitivity to rival that of the ELISA method, depending on assay parameters.

Genetic Assay Technology

MBL has developed a large number of reagents to support laboratory works from the extraction to detection of nucleic acids. In particular, our company has produced a number of in vitro diagnostics based on a PCR-reverse sequence-specific oligonucleotide probe (PCR-rSSO) method with Luminex® (xMAP®) technology, which is capable of simultaneously analysis of multiple types of genes. Recently, the company has introduced state-of-the art technologies for genetic assays, such as the real-time PCR method, next-generation DNA sequencers, and digital PCR technology, and is developing reagents capable of capturing gene information promptly and with high sensitivity to aid the diagnosis of cancers, infections, and other medical conditions. These reagents can help medical professionals to obtain information useful in designing personalized treatment, such as optimal therapeutic approach and choice of drugs.

Research Reagents

Various types of research reagents are used in life sciences including medicine. MBL is also engaged in the development of laboratory products in this area, utilizing the company’s afore-mentioned core technologies. Our product lines are diverse, as demonstrated by our research areas of various specific antibodies, novel biomarkers for the ELISA measurement system, enzyme activity measurement systems for drug screening, immune function diagnostic reagents (major histocompatibility complex [MHC] tetramers), protein fluorescent labeling reagents, etc. In these research and development activities, we are also pursuing potential future clinical diagnostics.

*1. Recombinant: Genetic engineering
*2. Autoantibody: An antibody reacting with antigenic constituents of the host’s tissue (or “self-antigen”) in autoimmune and other certain diseases

Full Site